Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H15N2O2.Cl |
Molecular Weight | 182.649 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].C[N+](C)(C)CCOC(N)=O
InChI
InChIKey=AIXAANGOTKPUOY-UHFFFAOYSA-N
InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H15N2O2 |
Molecular Weight | 147.1955 |
Charge | 1 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 |
6.0 mM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | MIOSTAT Approved UseIntraocular use for obtaining miosis during surgery. In addition, MIOSTAT (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery. Launch Date8.6486401E10 |
PubMed
Title | Date | PubMed |
---|---|---|
Spasmolytic constituents of Cedrus deodara (Roxb.) Loud: pharmacological evaluation of himachalol. | 1975 Feb |
|
Motor disturbances produced by intrastriatal injection of cyclic AMP and cyclic GMP. | 1976 Nov |
|
Midbrain interaction with the hypothalamus in expression of aggressive behavior in cats. | 1977 |
|
[Effects of atropine and scopolamine on the aggressive behavior and convulsions induced by carbachol and eserine injected into the cerebral ventricles of the cat]. | 1980 |
|
Seizures induced by carbachol, morphine, and leucine-enkephalin: a comparison. | 1983 Apr |
|
Neuropharmacology of the parasitic trematode, Schistosoma mansoni. | 1983 Jan |
|
Drug-induced modulation of locomotor hyperactivity induced by picrotoxin in nucleus accumbens. | 1984 Oct |
|
Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent". | 1984 Sep 3 |
|
Cholinergic induction of seizures in the rat prefrontal cortex. | 1986 Jun 23 |
|
Neuropeptide Y and calcitonin gene-related peptide: effects on glucagon and insulin secretion in the mouse. | 1987 |
|
Cardiovascular effects of cholinergic agents in the ventral-lateral midbrain periaqueductal gray of the rat. | 1987 Dec |
|
Novel 'soft' anticholinergic agents. | 1988 Feb |
|
The effect of cholinergic stimulation in the nucleus accumbens on locomotor behavior. | 1988 Feb 16 |
|
Anatomical analysis of frontal cortex sites at which carbachol induces motor seizures in the rat. | 1988 May |
|
Renal function during onset of carbachol-induced hypertension in conscious rats. | 1990 |
|
Catalepsy induced by carbachol microinjected into the pontine reticular formation of rats. | 1990 Jul 31 |
|
Positive and negative feedback regulation of choline acetyltransferase mRNA levels in Drosophila: a study using temperature-sensitive mutants and embryo cell cultures. | 1992 Apr |
|
Excitatory modulation by a spinal cholinergic system of a descending sympathoexcitatory pathway in rats. | 1992 Mar |
|
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
Zebrafish M2 muscarinic acetylcholine receptor: cloning, pharmacological characterization, expression patterns and roles in embryonic bradycardia. | 2002 Nov |
|
Regeneration of cardiomyocytes from bone marrow: Use of mesenchymal stem cell for cardiovascular tissue engineering. | 2003 Mar |
|
Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze. | 2003 Mar |
|
Metoclopramide causes airway smooth muscle relaxation through inhibition of muscarinic M3 receptor in the rat trachea. | 2004 May |
|
[Effects of carbachol on apoptosis of peripheral white blood cells and expression of cytokines in rats suffering from gut ischemia/reperfusion injury]. | 2005 Feb |
|
Neuronal nitric oxide synthase activity in rat urinary bladder detrusor: participation in M3 and M4 muscarinic receptor function. | 2005 Jul |
|
Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. | 2005 Jun |
|
Theoretical and experimental investigation of calcium-contraction coupling in airway smooth muscle. | 2006 |
|
Roles of protein kinase C, Ca2+, Pyk2, and c-Src in agonist activation of rat lacrimal gland p42/p44 MAPK. | 2006 Aug |
|
Muscarinic cholinoceptor activation modulates DNA synthesis and CD40 expression in fibroblast cells. | 2006 Jul |
|
Gene transfer of neuronal nitric oxide synthase into intracardiac Ganglia reverses vagal impairment in hypertensive rats. | 2007 Feb |
|
Metabotropic receptor-activated calcium increases and store-operated calcium influx in mouse Müller cells. | 2008 Jul |
|
Enhanced proliferation of SNU-407 human colon cancer cells by muscarinic acetylcholine receptors. | 2008 Nov 30 |
|
Monitoring the reaction of carbachol with acetylcholinesterase by thioflavin T fluorescence and acetylthiocholine hydrolysis. | 2008 Sep 25 |
|
Muscarinic receptors prevent oxidative stress-mediated apoptosis induced by domoic acid in mouse cerebellar granule cells. | 2009 Apr |
|
Histamine H1 receptor induces cytosolic calcium increase and aquaporin translocation in human salivary gland cells. | 2009 Aug |
|
The cholinomimetic agent carbachol induces headache in healthy subjects. | 2009 Feb |
|
Carbachol induces headache, but not migraine-like attacks, in patients with migraine without aura. | 2010 Mar |
|
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway. | 2010 Oct |
|
Molecular basis of inhibition of substrate hydrolysis by a ligand bound to the peripheral site of acetylcholinesterase. | 2010 Sep 6 |
|
Antispasmodic effects of eugenol on rat airway smooth muscle. | 2011 Dec |
|
TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes. | 2011 Feb 18 |
|
Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs). | 2011 Sep 25 |
|
Characterisation of acetylcholinesterase release from neuronal cells. | 2013 Mar 25 |
Patents
Sample Use Guides
MIOSTAT (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%
Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27118568
In the dose-course studies, carbachol showed significant increase in phosphorylation of MYPT1 at Thr696 (p-MYPT1) from concentrations of 15-100 μM based on Western blot results (p < 0.05, ANOVA test). In the time-course studies, treatment of cells with 15 μM of carbachol significantly enhanced the expression of p-MYPT1 from 3 to 15 h (p < 0.05, ANOVA test) and induced the expression of Rho A from 10 to 120 min (p < 0.05, ANOVA test).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:25:33 UTC 2022
by
admin
on
Fri Dec 16 16:25:33 UTC 2022
|
Record UNII |
8Y164V895Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29705
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
||
|
WHO-ATC |
S01EB02
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
||
|
WHO-ATC |
N07AB01
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
||
|
NDF-RT |
N0000175884
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
||
|
WHO-VATC |
QS01EB02
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
||
|
WHO-VATC |
QA03AB92
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5831
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
C47430
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
DB00411
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
32865
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
488
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
SUB06087MIG
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
298
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
M3051
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | Merck Index | ||
|
D002217
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
CHEMBL965
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
DTXSID9022730
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
3385
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
51-83-2
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
6373
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
1092009
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
1999
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | RxNorm | ||
|
383
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
Carbachol
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
200-127-3
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY | |||
|
Carbachol
Created by
admin on Fri Dec 16 16:25:34 UTC 2022 , Edited by admin on Fri Dec 16 16:25:34 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Duration of Action | PHARMACOKINETIC |
|
INTRAOCULAR ADMINISTRATION PHARMACOKINETIC |
|
||